Stock Price, News, Quote and Profile of SAB BIOTHERAPEUTICS INC(NASDAQ:SABS) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

SAB BIOTHERAPEUTICS INC

NASDAQ:SABS (12/18/2024, 10:26:02 AM)

4.06

+0.03 (+0.74%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustry

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%

Sales Q2Q%

CRS

6 Month41.9%

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap37.47M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

Short Float %

Short Ratio

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. The company is headquartered in Miami Beach, Florida and currently employs 57 full-time employees. The company went IPO on 2021-01-12. The firm's lead asset, SAB-142, targets type 1 diabetes (T1D) with a disease-modifying therapeutic approach. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, its DiversitAb drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, fully-human IgGs that can address a wide range of serious unmet needs in human diseases. The firm's SAB-176 pipeline program is a multivalent, broadly neutralizing -human polyclonal IgG therapeutic candidate in development for the treatment or prevention of severe influenza.

Company Info

SAB BIOTHERAPEUTICS INC

777 W 41St St, Suite 401

Miami Beach FLORIDA

P: 13058452813

CEO: Samuel J. Reich

Employees: 57

Website: https://www.sab.bio/

SABS News

9 days ago - ChartmillThese stocks are moving in today's after hours session

Monday's after hours session: top gainers and losers

a month ago - SAB Biotherapeutics, Inc.SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update...

2 months ago - SAB Biotherapeutics, Inc.SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

3 months ago - SAB Biotherapeutics, Inc.SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel...

SAB BIOTHERAPEUTICS INC (SABS)

Nasdaq Stock Screener

USA Stock Screener